Jane Street Group LLC Lowers Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET)

Jane Street Group LLC lessened its stake in shares of Adicet Bio, Inc. (NASDAQ:ACET) by 63.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,767 shares of the company’s stock after selling 132,269 shares during the quarter. Jane Street Group LLC’s holdings in Adicet Bio were worth $108,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. American Century Companies Inc. raised its holdings in Adicet Bio by 22.9% during the second quarter. American Century Companies Inc. now owns 76,087 shares of the company’s stock worth $92,000 after purchasing an additional 14,196 shares in the last quarter. Point72 DIFC Ltd increased its position in Adicet Bio by 77.5% during the 2nd quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock worth $40,000 after purchasing an additional 14,596 shares during the period. GSA Capital Partners LLP raised its stake in shares of Adicet Bio by 161.3% during the 3rd quarter. GSA Capital Partners LLP now owns 39,208 shares of the company’s stock worth $56,000 after buying an additional 24,203 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Adicet Bio by 14.9% in the 2nd quarter. XTX Topco Ltd now owns 259,788 shares of the company’s stock valued at $314,000 after buying an additional 33,739 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Adicet Bio in the second quarter valued at approximately $43,000. Hedge funds and other institutional investors own 83.89% of the company’s stock.

Adicet Bio Stock Up 4.0 %

Shares of ACET stock opened at $0.91 on Wednesday. The stock has a market cap of $74.92 million, a P/E ratio of -0.53 and a beta of 1.87. Adicet Bio, Inc. has a fifty-two week low of $0.81 and a fifty-two week high of $3.62. The business has a fifty day simple moving average of $1.01 and a 200-day simple moving average of $1.26.

Adicet Bio (NASDAQ:ACET) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, meeting the consensus estimate of ($0.34). On average, sell-side analysts anticipate that Adicet Bio, Inc. will post -1.39 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. StockNews.com cut Adicet Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. Guggenheim began coverage on shares of Adicet Bio in a report on Monday, September 30th. They issued a “buy” rating and a $7.00 price target for the company. Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of Adicet Bio in a report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Adicet Bio in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Adicet Bio presently has an average rating of “Hold” and a consensus target price of $7.50.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.